id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-1351-0058,FDA,FDA-2021-N-1351,Reference 2 - Molinaro (2010),Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:45:46Z,,0,0,09000064b91f30b7
FDA-2021-N-1351-0062,FDA,FDA-2021-N-1351,Reference 6 - RAND Corp (2004),Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:49:52Z,,0,0,09000064b91f413d
FDA-2021-N-1351-0059,FDA,FDA-2021-N-1351,Reference 3 - Carreiras M (2015),Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:46:45Z,,0,0,09000064b91f30b8
FDA-2021-N-1351-0063,FDA,FDA-2021-N-1351,Reference 7 - RTI (2015) Labeling Cost Model,Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:50:56Z,,0,0,09000064b91f413e
FDA-2021-N-1351-0064,FDA,FDA-2021-N-1351,Reference 8 - NDC-FRIA 2-20-26,Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:56:05Z,,0,0,09000064b91f413f
FDA-2021-N-1351-0056,FDA,FDA-2021-N-1351,Revising the National Drug Code Format and Drug Label Barcode Requirements,Rule,Final Rule,2026-03-05T05:00:00Z,2026,3,2026-03-05T05:00:00Z,,2026-03-05T19:38:29Z,2026-04368,0,0,09000064b91f375e
FDA-2021-N-1351-0061,FDA,FDA-2021-N-1351,Reference 5 - PRIA NDC Proposed Rule,Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:48:38Z,,0,0,09000064b91f413c
FDA-2021-N-1351-0057,FDA,FDA-2021-N-1351,Reference 1 - Grissinger M (2017),Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:44:35Z,,0,0,09000064b91f30b6
FDA-2021-N-1351-0060,FDA,FDA-2021-N-1351,Reference 4 - Nara S (2023),Supporting & Related Material,Background Material,2026-03-05T05:00:00Z,2026,3,,,2026-03-05T19:47:54Z,,0,0,09000064b91f413b
FDA-2021-N-1351-0005,FDA,FDA-2021-N-1351,"References 2 - Eastern Research Group, Inc. (2003), ‘‘The Pharmaceutical Labeling Revisions Cost Model’’",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:19Z,,0,0,09000064851ea766
FDA-2021-N-1351-0004,FDA,FDA-2021-N-1351,References 1 - HIPAA for Professionals,Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:13Z,,0,0,09000064851ea765
FDA-2021-N-1351-0008,FDA,FDA-2021-N-1351,"References 5 - RAND (2004), ""The Costs and Benefits of Moving to the ICD-10 Code Sets""",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:46Z,,0,0,09000064851ea769
FDA-2021-N-1351-0006,FDA,FDA-2021-N-1351,"References 3 - RTI International (2015), ‘‘2014 FDA
Labeling Cost Model’’",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:25Z,,0,0,09000064851ea767
FDA-2021-N-1351-0007,FDA,FDA-2021-N-1351,"References 4 - FDA, Preliminary Regulatory Impact Analysis, ‘‘Revising the National Drug Code Format and Drug Label Barcode Requirements""",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:32Z,,0,0,09000064851ea768
FDA-2021-N-1351-0001,FDA,FDA-2021-N-1351,Revising the National Drug Code Format and Drug Label Barcode Requirements,Proposed Rule,Advance Notice of Proposed Rulemaking (ANPRM),2022-07-25T04:00:00Z,2022,7,2022-07-25T04:00:00Z,2022-11-23T04:59:59Z,2022-12-17T02:00:33Z,2022-15414,0,0,09000064851e55bd